gastrointestinal tumors
Conditions
Interventions
experimental group 1:Ruineng enteral nutritional emulsion
experimental group 2:Dongzeli probiotic powder
experimental group 3:Ruineng enteral nutritional emulsion and Dongzeli probiotic powder
Sponsors
Lanzhou University Second Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Voluntarily participate in the trial and sign the informed consent; 2. According to clinical symptoms, signs and related imaging, pathological examination, as well as tumor markers, patients were definitely diagnosed as gastrointestinal tumors, including esophageal cancer, gastric cancer, duodenal cancer, liver cancer, gallbladder cancer, pancreatic cancer, colorectal cancer. 3.Patients with malignant tumors that cannot be treated by surgery and require transformation therapy or neoadjuvant therapy; 4. Those who have not taken antibiotics in the past 1 month; 5. With my consent and signed informed consent, I am willing and able to comply with the planned visit, research treatment, laboratory examination and other test procedures.
Exclusion criteria
Exclusion criteria: 1. Those who have received systematic treatment (including neoadjuvant chemotherapy, novel molecular targeted therapy and immunotherapy) before admission; 2. Used antibiotics in the past 1 month; 3. Severe active infections requiring intravenous antibiotic therapy occur during enrollment; 4. Those who cannot tolerate enteral nutrition; 5. Patients with intestinal obstruction and unable to eat; 6. Having multiple factors affecting oral medication (such as inability to swallow, chronic diarrhea, etc.); 7. History of splenectomy or thymus resection; 8. ICU admission due to critical condition; 9. Patients with any severe and/or uncontrolled disease, including: (1) A hypotensive drug is still not optimally controlled (systolic blood pressure >= 150 mmHg, diastolic blood pressure >= 100 mmHg); (2) Patients with grade I or higher myocardial ischemia or myocardial infarction, malignant arrhythmias (including QTC >= 480ms), and grade 2 or higher congestive heart failure (NYHA classification); (3) Decompensated liver disease; (4) Renal failure requires hemodialysis or peritoneal dialysis); (5) Have a history of immunodeficiency, including those who are HIV positive or have other acquired or congenital immunodeficiency disorders, or have a history of organ transplantation; (6) Poor diabetes control (fasting blood glucose (FBG)> 10mmol / L); (7) Patients with seizures who need treatment; 10. People with ineffectively controlled, symptomatic brain metastases, or a history of uncontrollable mental illness; Severe intellectual or cognitive dysfunction; 11. Subjects in need of systemic corticosteroids or other immunosuppressive drugs within 14 days prior to randomization; 12. Patients the investigator considers inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| intestinal flora;Immune checkpoints;Evaluation of immune function; | — |
Countries
China
Contacts
Public ContactChen Hao
Lanzhou University Second Hospital
Outcome results
None listed